{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T18:23:22Z","timestamp":1771871002389,"version":"3.50.1"},"reference-count":41,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Drug Development and Industrial Pharmacy"],"published-print":{"date-parts":[[2016,1,2]]},"DOI":"10.3109\/03639045.2015.1038272","type":"journal-article","created":{"date-parts":[[2015,7,6]],"date-time":"2015-07-06T13:44:39Z","timestamp":1436190279000},"page":"157-165","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of the tamper-resistant properties of biphasic immediate-release\/extended-release oxycodone\/acetaminophen tablets"],"prefix":"10.3109","volume":"42","author":[{"given":"Tiffani D.","family":"Eisenhauer","sequence":"first","affiliation":[{"name":"Mallinckrodt Pharmaceuticals, Hazelwood, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Matchett","sequence":"additional","affiliation":[{"name":"Mallinckrodt Pharmaceuticals, Hazelwood, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"Heasley","sequence":"additional","affiliation":[{"name":"Mallinckrodt Pharmaceuticals, Hazelwood, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terri","family":"Morton","sequence":"additional","affiliation":[{"name":"Mallinckrodt Pharmaceuticals, Hazelwood, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishna","family":"Devarakonda","sequence":"additional","affiliation":[{"name":"Mallinckrodt Pharmaceuticals, Hazelwood, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Giuliani","sequence":"additional","affiliation":[{"name":"Mallinckrodt Pharmaceuticals, Hazelwood, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim L.","family":"Young","sequence":"additional","affiliation":[{"name":"Mallinckrodt Pharmaceuticals, Hazelwood, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Barrett","sequence":"additional","affiliation":[{"name":"Mallinckrodt Pharmaceuticals, Hazelwood, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2015,7,6]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2008.10.008"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e31823c1030"},{"key":"CIT0003","unstructured":"World Health Organization. WHO\u2019s pain relief ladder. Available at: http:\/\/www.who.int\/cancer\/palliative\/painladder\/en\/ [last accessed 18 Mar 2014]"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.3109\/15360288.2012.757575"},{"key":"CIT0005","doi-asserted-by":"crossref","first-page":"401","DOI":"10.36076\/ppj.2010\/13\/401","volume":"13","author":"Manchikanti L","year":"2010","journal-title":"Pain Physician"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7517-8-29"},{"key":"CIT0007","unstructured":"US Food and Drug Administration. FDA blueprint for prescriber education for extended-release and long-acting opioid analgesics. Rockville (MD): Center for Drug Evaluation and Research; 2013:3292572"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1080\/J354v20n02_03"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.3109\/03639045.2012.680468"},{"key":"CIT0010","volume-title":"Full prescribing information","author":"Xartemis\u2122 XR (oxycodone hydrochloride and acetaminophen extended-release tablets)","year":"2014"},{"key":"CIT0011","author":"OxyContin\u00ae (oxycodone HCl extended release tablets)","year":"2011","journal-title":"Full prescribing information"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-200105000-00006"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2009.00320.x"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.876979"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.957824"},{"key":"CIT0016","unstructured":"FDA Guidance for Industry. Assessment of abuse potential of drugs. Draft guidance. January 2010. U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER). Available at: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM198650.pdf [last accessed 13 Jun 2014]"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2014.07.2780"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2012.698606"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2012.05.013"},{"key":"CIT0020","volume-title":"Guidance for industry abuse-deterrent opioids \u2013 evaluation and labeling","author":"Center for Drug Evaluation and Research","year":"2013"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1080\/03639040701377292"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2012.01380.x"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1080\/03639040500529093"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1111\/add.12114"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.12129"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1006\/faat.1995.1029"},{"key":"CIT0027","author":"OXECTA\u00ae (oxycodone HCl, USP)","year":"2011","journal-title":"Full prescribing information"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2012.0131"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2009.10.013"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2010.0028"},{"key":"CIT0031","author":"US Food and Drug Administration","year":"2009","journal-title":"FDA Advisory Committee on Reformulated OxyContin"},{"key":"CIT0032","author":"US Food and Drug Administration","year":"2013","journal-title":"Guidance for industry: abuse-deterrent opioids \u2013 evaluation and labeling"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2012.08.008"},{"key":"CIT0034","author":"US Food and Drug Administration","year":"2013","journal-title":"FDA approves abuse-deterrent labeling for reformulated OxyContin"},{"key":"CIT0035","unstructured":"Cassidy TA, McNaughton EC, Lobo K, et al. Abuse of reformulated OPANA\u00aeER: early findings from NAVIPPRO\u00aedata streams. Presented at: American Society of Addiction Medicine 44th Annual Medical-Scientific Conference; 2013 April 25\u201328; Chicago, IL"},{"key":"CIT0036","unstructured":"US Food and Drug Administration. FDA statement: original Opana ER relisting determination. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm351357.htm [last accessed 22 Jul 2014]"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1111\/pme.12295"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1204141"},{"key":"CIT0039","unstructured":"Drug Abuse Warning Network. US Department of Health and Human Services. Available at: https:\/\/dawninfo.samhsa.gov\/default.asp [last accessed 2 Jun 2010]"},{"key":"CIT0040","unstructured":"The Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) System. Denver Health. Available at: http:\/\/www.radars.org\/ [last accessed 30 Oct 2014]"},{"key":"CIT0041","unstructured":"National Addictions Vigilance Intervention and Prevention Program (NAVIPPRO). Inflexxion, Inc. Available at: http:\/\/inflexxion.com\/data_analysis_services\/ [last accessed 30 Oct 2014]"}],"container-title":["Drug Development and Industrial Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.3109\/03639045.2015.1038272","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T18:02:47Z","timestamp":1652810567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.3109\/03639045.2015.1038272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,6]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1,2]]}},"alternative-id":["10.3109\/03639045.2015.1038272"],"URL":"https:\/\/doi.org\/10.3109\/03639045.2015.1038272","relation":{},"ISSN":["0363-9045","1520-5762"],"issn-type":[{"value":"0363-9045","type":"print"},{"value":"1520-5762","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iddi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iddi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-08-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-03-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-07-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}